Kuwana M - Search Results

1

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP; focuSSced investigators. Khanna D, et al. Among authors: kuwana m. Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28. Lancet Respir Med. 2020. PMID: 32866440 Clinical Trial.

2

Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis.

Hata R, Akai J, Kimura A, Ishikawa O, Kuwana M, Shinkai H. Hata R, et al. Among authors: kuwana m. Biochem Biophys Res Commun. 2000 May 27;272(1):36-40. doi: 10.1006/bbrc.2000.2731. Biochem Biophys Res Commun. 2000. PMID: 10872800

3

Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma.

Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N, Tamaki K. Yamane K, et al. Among authors: kuwana m. Rheumatology (Oxford). 2001 Jun;40(6):683-6. doi: 10.1093/rheumatology/40.6.683. Rheumatology (Oxford). 2001. PMID: 11426027

4

Anti-U1RNP antibodies in patients with localized scieroderma.

Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N, Tamaki K. Yamane K, et al. Among authors: kuwana m. Arch Dermatol Res. 2001 Sep;293(9):455-9. doi: 10.1007/s004030100254. Arch Dermatol Res. 2001. PMID: 11758788

5

Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap.

Kubo M, Ihn H, Kuwana M, Asano Y, Tamaki T, Yamane K, Tamaki K. Kubo M, et al. Among authors: kuwana m. Rheumatology (Oxford). 2002 May;41(5):531-4. doi: 10.1093/rheumatology/41.5.531. Rheumatology (Oxford). 2002. PMID: 12011376

6

[Clinical evaluation methods in patients with systemic sclerosis].

Kuwana M, Sato S, Kondo H, Takehara K. Kuwana M, et al. Ryumachi. 2002 Aug;42(4):654-65. Ryumachi. 2002. PMID: 12355860 Review. Japanese. No abstract available.

7

Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis.

Kuwana M, Sato S, Kikuchi K, Kawaguchi Y, Fujisaku A, Misaki Y, Hatamochi A, Kondo H, Takehara K. Kuwana M, et al. J Rheumatol. 2003 Jun;30(6):1253-8. J Rheumatol. 2003. PMID: 12784399

8

The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis.

Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, Kondo M, Nishijima C, Hayakawa I, Ogawa F, Kuwana M, Takehara K, Sato S. Hamaguchi Y, et al. Among authors: kuwana m. Br J Dermatol. 2008 Mar;158(3):487-95. doi: 10.1111/j.1365-2133.2007.08392.x. Epub 2008 Jan 17. Br J Dermatol. 2008. PMID: 18205876 Free PMC article.

9

Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy.

Shima Y, Kawaguchi Y, Kuwana M. Shima Y, et al. Among authors: kuwana m. Mod Rheumatol. 2019 Jan;29(1):134-139. doi: 10.1080/14397595.2018.1452178. Epub 2018 Apr 9. Mod Rheumatol. 2019. PMID: 29529897 Clinical Trial.

10

The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method.

Yajima N, Tsujimoto Y, Fukuma S, Sada KE, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura-Ogasawara M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, Atsumi T. Yajima N, et al. Among authors: kuwana m. Mod Rheumatol. 2020 May;30(3):525-531. doi: 10.1080/14397595.2019.1621419. Epub 2019 Jun 26. Mod Rheumatol. 2020. PMID: 31111758

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

550 results

Search Page